hotspot -WSS

hotspot

author：knowledge 2025-09-06 10:18:22 - browse：98477

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： STAT Readout Newsletter: Biotech news today

entertainment

WSS

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Why a market frenzy over new weight loss drugs defies logic

STAT Virtual Event: ASCO Recap, Live!

STAT Summit: How researchers deal with rejection

Readout LOUD podcast: Live from the 2023 STAT Summit

UnitedHealth, Optum discontinue NaviHealth name

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Novavax promises a turnaround & Lilly roils the obesity market

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Guidelines to prevent youth baseball injuries need more muscle

Smaller biotechs seek to piggyback on weight loss drug boom

Psychedelics group wrestles with new pharma identity

My daughter's legacy lives on through her writing, phage therapy

Drug repurposing or repositioning? The language matters

Is there really a nursing shortage in the U.S.?

entertainment

ALS patient reclaims some autonomy thanks to wearable 'robot'

UnitedHealth, Optum discontinue NaviHealth name

Moderna says combo Covid

UnitedHealth, Optum discontinue NaviHealth name

STAT Summit: How researchers deal with rejection

Health care court cases: Humana, Sutter, Novant

entertainment

entertainment

knowledge

knowledge